Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : dsco Discovery Laboratories -- Ignore unavailable to you. Want to Upgrade?

To: Alex Glavinos who wrote (16)	5/10/1999 2:46:00 PM
From: FFNEODOC	Respond to of 318

Good news... The lavage treatment for ARDS is an extension of the work that looks extremely promising to treat MAS in babies. Expect this good news will continue, but the big payday for this stock, we all know, is contingent on FDA approval for Surfaxin for one of the multiple clinical trials. I still think the most likely first FDA indication will be the MAS in babies trial, since this is already in phase 3 & on the FDA fast track. Frank